COUR Pharmaceuticals

About COUR Pharmaceuticals

COUR Pharma is dedicated to developing targeted therapies that reprogram the immune system to treat autoimmune diseases, aiming to restore health and balance by stopping inflammatory destruction while preserving normal immune function.

Products & Services

Platform Technology:A versatile platform using an antigen-specific approach to treat underlying autoimmune diseases, leveraging the body's self-tolerance pathways for a wide range of immune-mediated conditions.

Pipeline Therapies:Next-generation disease-modifying therapies designed to restore immune system balance and transform care standards for various immune-mediated diseases.

CNP-103 Clinical Trial:A clinical trial focused on Type 1 Diabetes treatment.

Specialties

Immune System Reprogramming Autoimmune Disease Treatment Antigen-Specific Therapies Disease-Modifying Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 105000000 MR: - FA: $105 million FAN: 105000000	D: 2024-01-30 FD: 2024-01-30	7 investors

Series A Latest

2024-01-30

$105.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dannielle Appelhans

President and CEO

LinkedIn (Pro only)

B

Brian C. Bock

Chief Financial Officer

LinkedIn (Pro only)

P

Paul M. Peloso

Chief Medical Officer

LinkedIn (Pro only)

S

Sarah Longoria

Chief People Officer

A

Adam Elhofy

VP, Research

R

Robert Hodge

VP, Technical Development

View 24 more team members with Pro

Unlock Full Team Directory

Recent News